2023
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2019
Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls
Buza N. Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. Archives Of Pathology & Laboratory Medicine 2019, 143: 47-64. PMID: 30785337, DOI: 10.5858/arpa.2018-0289-ra.Peer-Reviewed Original ResearchConceptsFrozen section evaluationOvarian epithelial tumorsIntraoperative frozen section evaluationFrozen section diagnosisEpithelial tumorsOvarian tumorsSection evaluationSection diagnosisClear cell ovarian tumorsExtensive staging proceduresExtent of surgeryCareful gross examinationPreoperative diagnostic workupCommon clinical scenariosAccurate frozen section diagnosisSignificant diagnostic challengePotential diagnostic pitfallFrozen section laboratorySurgical stagingStaging procedureYounger patientsBorderline tumorsSerum markersOvarian massesDiagnostic challenge